Gitnux/Report 2026

Global Autism Statistics

Autism looks similar on paper worldwide, yet the figures swing dramatically from about 1% global prevalence to higher identification rates in specific settings and reveal why access and early support still vary so much. Find 2025 ready takeaways on costs, comorbidities, and what helps, alongside service access gaps such as the 56% of U.S. children ages 3 to 17 with autism who lacked enough health insurance for needed services.
40Statistics
40Sources
6Sections
1Visuals
8mRead
2 mo agoUpdated
Global Autism Statistics
Priya ChandrasekaranWritten by Priya Chandrasekaran·Edited by David Sutherland·Fact-checked by Katherine Brennan
Last verified Jun 27, 2026
Verified via a 4-step process
01Source

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Verify

Each statistic is independently verified via reproduction analysis and cross-referencing against independent databases.

03Grade

Figures are graded by cross-model consensus. Statistics failing independent corroboration are excluded regardless of how widely cited.

04Cite

Every figure carries a primary source. We maintain stable URLs and versioned verification dates so the report can be cited.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

Within the next 32 days
UNICEF estimates 75 million children worldwide live with autism spectrum disorder. Global prevalence is often placed around the 1% mark, but diagnosis and care access are not evenly distributed. In the U.S., 56% of children aged 3 to 17 with autism had no or not enough health insurance for services they needed.

Key Takeaways

  • In the U.S., ASD identification is 4 times higher among children with intellectual disability than among those without (CDC surveillance context)
  • The global prevalence of ASD is estimated at 1% (systematic review estimate)
  • ASD prevalence was estimated at 1.7% in a meta-analysis of global studies
  • In the U.S., 56% of children aged 3–17 with autism had no or not enough health insurance for services they needed (National Health Interview Survey-based estimate)
  • In the U.S., the median age of first ASD evaluation was 7 years in 2019 (parents reported timing; CDC ADDM report context)
  • In Australia, autism affects about 1 in 100 people (reported in Australian government disability statistics brief)
  • The global autism market had a compound annual growth rate (CAGR) forecast of 9.6% during 2023–2030 (market forecast from vendor research)
  • The autism treatment market is forecast to grow at a CAGR of 8.9% from 2024 to 2032 (IMARC forecast)
  • Telehealth adoption for ASD-related therapy expanded; 2020–2021 saw rapid scaling of telehealth services for developmental disorders (CDC/health system survey context)
  • The autism therapeutics market size was valued at $7.8 billion in 2022 (industry market sizing)
  • The global autism diagnostic and screening tests market is projected to grow to $6.9 billion by 2030 (industry forecast)
  • In the U.S., autism care costs average about $60,000 per year per child (peer-reviewed cost estimate commonly cited by CDC)
  • In randomized trials, Early Intensive Behavioral Intervention (EIBI) improved IQ by about 3–9 points relative to control conditions in pooled analyses (meta-analysis)
  • A meta-analysis found that behavioral interventions for young children with ASD produce moderate improvements in social communication (standardized effect sizes reported)
  • A systematic review of parent-mediated interventions reported improvement in ASD core symptoms with an average standardized mean difference of ~0.4 (pooled meta-analytic estimate)

With about 1% global prevalence and rising awareness, access to early, effective autism support remains critical worldwide.

Related reading

01 · Category

Prevalence Rates6 stats

01
In the U.S., ASD identification is 4 times higher among children with intellectual disability than among those without (CDC surveillance context)
02
The global prevalence of ASD is estimated at 1% (systematic review estimate)
03
ASD prevalence was estimated at 1.7% in a meta-analysis of global studies
04
In a global review of epidemiology studies, pooled ASD prevalence ranged from 0.62% to 1.31% depending on method and setting
05
In 2019, an estimated 75 million children globally were living with autism spectrum disorder (UNICEF global estimate)
06
An estimated 31% of children with ASD in the U.S. had at least one comorbidity (CDC surveillance context)
Interpretation

Prevalence Rates Interpretation

Across prevalence rates, autism spectrum disorder is consistently estimated at about 1% globally, with meta-analyses showing a rise to roughly 1.7% and pooled studies ranging from 0.62% to 1.31%, translating to an estimated 75 million children worldwide living with ASD in 2019.

02 · Category

Diagnosis & Access3 stats

01
In the U.S., 56% of children aged 3–17 with autism had no or not enough health insurance for services they needed (National Health Interview Survey-based estimate)
02
In the U.S., the median age of first ASD evaluation was 7 years in 2019 (parents reported timing; CDC ADDM report context)
03
In Australia, autism affects about 1 in 100 people (reported in Australian government disability statistics brief)
Interpretation

Diagnosis & Access Interpretation

For the Diagnosis & Access category, the gap is stark, with 56% of U.S. children ages 3–17 with autism lacking adequate health insurance, and the first ASD evaluation occurring at a median age of 7 years, while Australia reports a prevalence of about 1 in 100 people, underscoring how access barriers can delay support even as incidence remains significant.

More related reading

04 · Category

Market & Economics7 stats

01
The autism therapeutics market size was valued at $7.8 billion in 2022 (industry market sizing)
02
The global autism diagnostic and screening tests market is projected to grow to $6.9 billion by 2030 (industry forecast)
03
In the U.S., autism care costs average about $60,000per year per child (peer-reviewed cost estimate commonly cited by CDC)
04
In the U.S., lifetime costs for an individual with ASD are estimated at $2.4 million (U.S. cost-of-illness estimate by peer-reviewed research)
05
In the U.S., annual costs of ASD to society were estimated at $461 billion (2007 estimate; widely cited peer-reviewed analysis)
06
In the U.S., early intervention costs per child with ASD were estimated around $4,967–$18,830 depending on intensity (systematic cost analysis range)
07
Direct healthcare spending for ASD-related conditions in the U.S. was about $137 billion in 2016 (peer-reviewed national estimate)
Interpretation

Market & Economics Interpretation

The market and economics data show strong growth and substantial spending needs, with autism therapeutics reaching $7.8 billion in 2022 and autism diagnostic and screening tests projected to hit $6.9 billion by 2030, while U.S. costs average about $60,000 per child each year and lifetime costs can reach $2.4 million, underscoring a large and expanding financial opportunity in the autism care ecosystem.

05 · Category

Therapy & Outcomes9 stats

01
In randomized trials, Early Intensive Behavioral Intervention (EIBI) improved IQ by about 3–9 points relative to control conditions in pooled analyses (meta-analysis)
02
A meta-analysis found that behavioral interventions for young children with ASD produce moderate improvements in social communication (standardized effect sizes reported)
03
A systematic review of parent-mediated interventions reported improvement in ASD core symptoms with an average standardized mean difference of ~0.4 (pooled meta-analytic estimate)
04
A meta-analysis reported that social skills training yields small-to-moderate improvements in social functioning for youth with ASD (effect size reported)
05
Cognitive behavioral therapy (CBT) for anxiety in ASD shows improvements; a meta-analysis reported a standardized effect size around 0.6 (pooled estimate)
06
Exercise interventions in ASD: a meta-analysis found improvements in behavioral symptoms with a pooled effect size of about 0.5 (standardized mean difference)
07
Melatonin is commonly used for sleep problems in ASD; randomized controlled trials show it reduces sleep onset latency by about 30–45 minutes (systematic review estimate)
08
In a systematic review, occupational therapy interventions improved adaptive skills with a standardized effect size reported as ~0.4 (meta-analysis)
09
A large randomized clinical trial found that parent training improved adaptive behavior outcomes compared with control, with improvements on adaptive behavior measures reported as clinically meaningful (trial effect sizes)
Interpretation

Therapy & Outcomes Interpretation

Across Therapy & Outcomes studies, multiple intervention types show measurable benefits, including EIBI improving IQ by roughly 3–9 points and meta-analytic effect sizes hovering around 0.5 to 0.6 for social skills, anxiety CBT, and exercise, while behavioral and parent-mediated programs deliver moderate gains in core social communication symptoms.

06 · Category

Regulation & Public Policy6 stats

01
The FDA has approved only a small number of ASD-specific pharmacologic indications; 2 atypical antipsychotics (risperidone and aripiprazole) are approved for irritability in ASD (FDA approvals)
02
UNICEF estimated that 1 in 70 children globally has autism spectrum disorder (UNICEF/WHO global health estimate often cited in UNICEF communications)
03
UK Department of Health and Social Care policy documents report that Autism Act duties require local authorities to support people with autism (Autism strategy implementation policy)
04
The U.S. Autism CARES Act provided $1 billion for autism research and services over 5 years (U.S. legislation summary)
05
The U.S. CURES Act directed $1.1 billion for opioid/substance use and included provisions related to autism and research funding (U.S. act text summary; autism-related sections)
06
WHO calls autism a developmental condition with substantial global public health implications; WHO’s 2023/2024 autism and neurodevelopment materials emphasize population-level planning (WHO webpage for autism spectrum disorders)
Interpretation

Regulation & Public Policy Interpretation

Across regulation and public policy, autism is increasingly recognized as a global public health priority, with UNICEF estimating 1 in 70 children worldwide and governments funding action, including the US Autism CARES Act’s $1 billion over 5 years and WHO highlighting major implications, while medication approvals remain limited to just a small number of ASD specific pharmacologic indications in the FDA record.
report visual · Comparison

Global autism prevalence: point estimates vs pooled range

Global autism spectrum disorder (ASD) prevalence is estimated around 1%, with meta-analytic findings showing a pooled range depending on method and setting.

ASD prevalence was estimated at 1.7% in a meta-analysis of global studies1.7%
The global prevalence of ASD is estimated at 1% (systematic review estimate)
1%
In a global review of epidemiology studies, pooled ASD prevalence ranged from 0.62% to 1.31% depending on method and set
0.62%
source-verifiedpubmed.ncbi.nlm.nih.gov
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Priya Chandrasekaran. (2026, February 13). Global Autism Statistics. Gitnux. https://gitnux.org/global-autism-statistics
MLA
Priya Chandrasekaran. "Global Autism Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/global-autism-statistics.
Chicago
Priya Chandrasekaran. 2026. "Global Autism Statistics." Gitnux. https://gitnux.org/global-autism-statistics.

Sources & references

40 datasets cited across this report · attribution is report-level

cdc.govpubmed.ncbi.nlm.nih.govunicef.orgaihw.gov.auglobenewswire.comalliedmarketresearch.comfortunebusinessinsights.comimarcgroup.comjamanetwork.comncbi.nlm.nih.govfda.govlegislation.gov.ukcongress.govwho.intclinicaltrials.gov

+25 additional datasets cited (not shown individually)